Education, Science, Technology, Innovation and Life
Open Access
Sign In
  1. Home
  2. Journals
  3. MEDS Chinese Medicine
  4. Vol 7, Issue 3, 2025

Clinical Evidence Map of Traditional Chinese Medicine for Treating Menopausal Hypertension

Download as PDF

DOI: 10.23977/medcm.2025.070320 | Downloads: 2 | Views: 76

Author(s)

Shuai Wang 1, Hongsen Du 2, Zhen Ma 2

Affiliation(s)

1 Shaanxi University of Chinese Medicine, Xianyang, 712046, Shaanxi Province, China
2 Xi'an Hospital of Traditional Chinese Medicine, Xi'an, 710021, Shaanxi Province, China

Corresponding Author

Zhen Ma

ABSTRACT

This study systematically summarizes the clinical research methods and efficacy of Traditional Chinese Medicine (TCM) in treating menopausal hypertension to provide clinical reference. Databases including CNKI, PubMed, and Cochrane Library were searched up to April 30, 2025, with evidence summarized via figures, tables, and text. A total of 164 randomized controlled trials (RCTs) and 3 meta-analyses were included. Over 70% of studies had sample sizes ranging from 60 to 100 cases, with treatment protocols mainly combining TCM and Western medicine, where oral herbal decoctions were the most common intervention and control groups typically received Western antihypertensive medications. Outcome indicators primarily focused on blood pressure and clinical efficacy rates. However, included RCTs demonstrated high risk of bias due to inadequate allocation concealment and insufficient blinding procedures, while meta-analyses received poor methodological evaluations owing to lack of protocol registration and incomplete literature searches. Current research exhibits significant flaws in study design, lacks comparative studies between different TCM treatment regimens, and demonstrates insufficient reporting of key outcome indicators, which collectively restrict the credibility and applicability of research findings. Limitations must be addressed to provide more robust evidence-based support for TCM in the prevention and treatment of menopausal hypertension.

KEYWORDS

Traditional Chinese Medicine; Menopausal Hypertension; Clinical Research Characteristics; Randomized Controlled Trial; Evidence Map

CITE THIS PAPER

Shuai Wang, Hongsen Du, Zhen Ma, Clinical Evidence Map of Traditional Chinese Medicine for Treating Menopausal Hypertension. MEDS Chinese Medicine (2025) Vol. 7: 156-165. DOI: http://dx.doi.org/10.23977/medcm.2025.070320.

REFERENCES

[1] Zong, Z., Jin, X. S., & Yuan, K. C. (2024). Research progress on the pathogenesis and treatment of menopausal hypertension. Chinese Journal of Gerontology, 44(3), 756-759.
[2] Preuss, H. G., & Burris, J. F. (1996). Adverse metabolic effects of antihypertensive drugs. Implications for treatment. Drug Safety, 14(6), 355–364.
[3] Insani, W. N., Wei, L., Abdulah, R., & Wändell, P. E. (2025). Exploring the association of adverse drug reactions with medication adherence and quality of life among hypertensive patients: a cross-sectional study. International Journal of Clinical Pharmacy, 47(2), 354-364.
[4] Yusufu, Z., Yusufu, Z., & Liu, Y. M. (2018). Effect of Qianyang mixture on sex hormone levels in perimenopausal hypertension. Electronic Journal of Cardiovascular Diseases of Integrated Traditional Chinese and Western Medicine, 6(30), 86-87.
[5] Lin, X., Lei, Z. Y., & Yu, C. Y. (2008).Effect of Xuzao Gengping granule on blood pressure variability in female menopausal hypertension. Journal of Xinjiang Medical University, 31(12), 1753-1756.
[6] Zhu, X., Liew, Y., & Liu, Z. L. (2016). Chinese herbal medicine for menopausal symptoms. Cochrane Database of Systematic Reviews, (3).
[7] Zhang, K. X., Li, X., & Chen, K. L. (2025). Evidence map analysis of clinical research on traditional Chinese medicine treatment of renal anemia. China Journal of Chinese Materia Medica.
[8] Zhang, F. Y., Shen, A. M., & Zeng, X. T. (2018). Interpretation of AMSTAR 2: a critical appraisal tool for systematic reviews. Chinese Journal of Evidence-Based Cardiovascular Medicine, 10(1), 14-18.
[9] Ma, L., Wang, Z. R., & Ma, J. (2011). Clinical observation on modified Erxian decoction in treating perimenopausal hypertension. Journal of Guiyang College of Traditional Chinese Medicine, 33(4), 13-14.
[10] Hao, R. L. (2018). Efficacy of TCM method of calming liver and suppressing yang in treating perimenopausal hypertension. Electronic Journal of Cardiovascular Diseases of Integrated Traditional Chinese and Western Medicine, 6(17), 153-154.
[11] Sun, Y. Q. (2021). Effect of clustered traditional Chinese medicine intervention on blood pressure in patients with menopausal syndrome hypertension of liver qi stagnation type. Yinshi Baojian (Diet and Health), (31), 111-112.
[12] Wang, B., Du, M. M., & Wang, C. Y. (2024).Clinical efficacy of Zishen Ningxin Capsule combined with telmisartan in the treatment of perimenopausal hypertension. Chinese Journal of Pharmacoepidemiology, 33(1), 52-59.
[13] Kario, K., Okura, A., Hoshide, S., & Harada, N. (2024). The WHO global report 2023 on hypertension warning the emerging hypertension burden in globe and its treatment strategy. Hypertension Research, 47(5), 1099–1102.
[14] Sun, L. M., & Xue, Y. X. (2020).A brief discussion on the experience of national master of traditional Chinese medicine Xue Boshou in using Erxian decoction. Tianjin Journal of Traditional Chinese Medicine, 37(2), 171-175.
[15] Du, X. L., Zhu, Y., & Li, J. (2022).Effect of Erxian decoction on menopausal hypertension by mediating glucocorticoid signaling pathway. Chinese Journal of Traditional Chinese Medicine, 37(7), 4091-4095.
[16] Chinese Society of Traditional Chinese Medicine. (2024).Expert consensus on the clinical application of Songling Xuemai Kang capsule in the treatment of primary hypertension. Chinese Journal of Hypertension, 32(1), 8-15.
[17] Liu, W., Wang, J., & Zhao, Y. Q. (2015). Study on the regulatory mechanism of Songling Xuemai Kang capsule on RAAS system in spontaneously hypertensive rats. Chinese Journal of Traditional Chinese Medicine, 30(4), 1322-1324.
[18] Yu, Q., Li, X., & Yang, Y. (2011). Effect of Songling Xuemai Kang on pulse wave velocity and vascular endothelial function in patients with hypertension. West China Journal of Pharmaceutical Sciences, 26(3), 298-299.
[19] Liu, L., Chen, Y. M., & Zhou, Y. J. (2017).The effect and mechanism of Songling Xuemai Kang capsule on intervening atherosclerosis in rats. Science Technology and Engineering, 17(26), 185-188.
[20] Sun, H., & Sun, Y. (2017). Therapeutic effect of Songling Xuemai Kang combined with candesartan cilexetil on hypertension of yin deficiency and yang hyperactivity type in menopausal women. Modern Drugs and Clinic, 32(3), 496-499.
[21] Shang, Y. H., & Lin, X. (2011). Clinical observation on Songling Xuemai Kang capsule in treating menopausal hypertension. Journal of Cardiovascular and Cerebrovascular Diseases of Integrated Traditional Chinese and Western Medicine, 9(4), 413-414.
[22] Zeng, Y. Z., & Chen, S. Y. (2018).Selection of outcome measures and sample size estimation in clinical research. Medical Journal of Peking Union Medical College Hospital, 9(1), 87-92.
[23] Lu, S., Taddei, I., & Abbate, E. (2024). The pathophysiology, prognosis and treatment of hypertension in females from pregnancy to post-menopause: A review. Current Heart Failure Reports, 21(4), 226-236.
[24] Yusuf, S., Hawken, S., Ounpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Budaj, A., Pais, P., Varigos, J., & Lisheng, L. (2004). Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the1 INTERHEART study): case-control study. The Lancet, 364(9438), 937-952.
[25] Appiah, D., Schreiner, P. J., Demerath, E. W., & Wellons, M. (2016). Association of age at menopause with incident heart failure: a prospective cohort study and meta-analysis. Journal of the American Heart Association, 5(9), e003943.
[26] Saw, J., Humphries, K., Aymong, E., Sedlak, T., Prakash, R., Starovoytov, A., & Mancini, G. B. J. (2017). Spontaneous coronary artery dissection: clinical outcomes and risk factors. Journal of the American College of Cardiology, 70(9), 1148-1158.
[27] Yoon, B. K., Sung, J., Song, Y. M., & Lee, K. (2021). Effects of menopausal hormone therapy on ambulatory blood pressure and arterial stiffness in postmenopausal Korean women with grade 1 hypertension: a randomized, placebo-controlled trial. Clinical Hypertension, 27(1), 1-9.
[28] Yang, Y., & Shen, Y. L. (2023). Clinical study on the effect of Tianma Gouteng Yin combined with “reverse acupuncture” at Sigu points on blood pressure and carotid intima-media thickness in prehypertensive perimenopausal women. Chinese Science and Technology Journal Database (Full-text Edition) Medicine and Health, (10), 135-139.
[29] Li, Y. Y., Hu, J., & Qin, Z. H. (2012).Clinical study on Jiawei Xiaoyao pill combined with valsartan in treating perimenopausal hypertension. New Journal of Traditional Chinese Medicine, 44(12), 63-65.
[30] Lima, R., Wofford, M., & Reckelhoff, J. F. (2012). Hypertension in postmenopausal women. Current Hypertension Reports, 14(3), 254-260.
[31] Zheng, M., Xu, X., Wang, X., Guan, T., Lu, Z., & Chen, Y. (2014). Age, arterial stiffness, and components of blood pressure in Chinese adults. Medicine, 93(29), e262.
[32] Maas, A. H., & Franke, H. R. (2009). Women’s health in menopause with a focus on hypertension. Netherlands Heart Journal, 17(2), 68-72.
[33] Schulz, K. F., Chalmers, I., Hayes, R. J., & Altman, D. G. (1995). Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA, 273(5), 408-412.

Subscription
E-Mail Alert
Most popular papers
Call for Special Issue
Publication Ethics & OA Statement
Plagiarism Policy
Contact Us
Downloads: 9003
Visits: 587118

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.